Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

Inclusion Criteria: * Subjects with history of chronic idiopathic intestinal pseudo-obstruction or CIPO secondary to neurodegenerative or demyelinating disease. * Subjects with estimated oral caloric intake of at least 30% of the daily age- and sex-recommended caloric intake. * Subjects with at least 2 out of 4 CIPO gastrointestinal symptoms each of the 2 with a score ≥3 (on a 0 to 4 scale) at Day -1 * Subjects accepting to provide and legally capable of providing free and informed consent to all procedures included in the protocol. * All sexually active male participants who are partner of women of childbearing potential must use condom during intercourse until the 90th day after the end of the entire study. * Female participants are eligible if they are: i) of non-childbearing potential or ii) of childbearing potential with a negative pregnancy test result at screening and randomization AND agreeing to use a highly effective method of contraception (i.e., with failure rate of less than 1% per year) until the end of the entire study. Exclusion Criteria: * Subjects with primary CIPO or CIPO secondary to other known endocrine/metabolic, autoimmune diseases and neurologic conditions other than neurodegenerative or demyelinating diseases. * Subjects with conditions characterized by mechanical intestinal obstruction. * Nasogastric tube, gastrostomy tube, or jejunostomy feeding tube in place at randomization or planned throughout the duration of the study, or artificial food ne…